The etiology of bacteremia in febrile neutropenic patients in the past few decades has shifted from gramnegative to gram-positive organisms. Potential reasons include the use of indwelling catheters, local environmental conditions, and the administration of specific antibiotic agents, especially as prophylaxis. Other factors may emerge from new studies, such as the categorization of febrile neutropenic patients into groups at low risk and at high risk of developing serious complications, continuing changes in resistance in the community, the use of antibiotic-coated catheters, and future changes in cytotoxic chemotherapy or antineoplastic therapy. In addition, there has been a drift in susceptibility patterns, with resistance issues seen in the general population of hospitalized patients now emerging in febrile neutropenic patients, as well as some issues specific to these patients. These changes affect empirical therapy as it was practiced a decade ago. Among the most commonly used agents, cefepime and carbapenems continue to show the highest rates of in vitro susceptibility, providing coverage against most gram-positive and gram-negative organisms and reducing the need for glycopeptides. Older agents continue to show degradation of their effectiveness. Among Pseudomonas aeruginosa strains, susceptibility to all agents continues to decline.
aeruginosa, and began increasing again with the use of long-term indwelling catheters [3] . Bacteremia due to gram-negative organisms became less prevalent because of the use of prophylactic antimicrobial regimens, rather than because of some other recognized factor. Attempts to clarify why these changes occurred have led to the identification of other factors that have had some impact on the etiology of infections, but antibiotic use remains the most important determinant (see below).
GENERAL FACTORS AFFECTING THE ETIOLOGY OF BACTEREMIA
The etiology of febrile neutropenia, as reported in the literature, is subject to variations that are dependent on a variety of factors. Some of these factors have specific biases that are not discussed as such in published studies, which calls for caution in generalizing the often-reported "shift" in etiology. The increased use of indwelling catheters, allowing colonization and infection by skin flora, mostly gram-positive organisms, is a major factor [1, 4] , but in locations where long-term indwelling catheters are not commonly used, this may not hold true.
The incidence of resistance in the community to agents used for antibiotic prophylaxis is not mentioned as a determining factor. In Barcelona, however, there was a sudden resurgence of E. coli bacteremia among febrile neutropenic patients [5] after the use of quinolone prophylaxis; this resurgence was thought to have occurred because of the very high prevalence of fluoroquinolone-resistant strains of E. coli in the general community. Thus, it is likely that, in areas of the world where there is rampant fluoroquinolone resistance [6, 7] , bacteremia due to gram-negative organisms will be the dominant type of bacteremia. In some specific populations, such as bone marrow transplant recipients, among whom viridans streptococci is a predominant organism causing bacteremia [8] , the effect of the prophylactic agent on the etiology of bacteremia may even be more confounding. For example, the use of broader-spectrum prophylactic antibiotics with activity against both gram-positive and gram-negative organisms, such as some advanced fluoroquinolones, may result in fewer cases of infection with viridans streptococci and fewer cases due to enteric gram-negative organisms, perhaps with the occurrence of some unforeseen change or a preponderance of staphylococcal infection. Thus, reports of the bacterial etiology of febrile neutropenia should always be considered in light of the antibiotic prophylaxis used and the levels of resistance to the prophylactic agents.
The nature of the chemotherapy used has also been reported to influence the bacterial etiology of febrile neutropenia [1] . Therefore, changes in chemotherapy can be expected to play a role in the etiology of bacteremia. The use of more specific agents with less cytotoxic potential and, therefore, less mucosal toxicity can lead to a reduction in infections due to viridans streptococci, enterococci, and enteric gram-negative organisms. Thus, these counter-prevailing forces will cause changes in what is reported in studies, and each institution will need to make decisions about empirical therapy on the basis of these factors.
One overlooked factor may even be the regional climactic or environmental conditions that may affect the etiology. For example, P. aeruginosa infection appears to be more prevalent in warmer climates. It accounted for as many as 27% of pathogens isolated from febrile neutropenic patients an Indian hospital [9] . Therefore, data that are reported from the United States and Europe may not be fully representative of what is seen as the bacterial etiology of febrile neutropenia in developing nations, and specific institutions may not show the general pattern if they eschew antibiotic prophylaxis.
Another potential determinant of shifts in etiology in published studies is the categorization of febrile neutropenic patients into groups at low risk and high risk of developing serious complications, because such patients are likely to be represented among future large-scale studies, given the current emphasis on treating low-risk populations at home. It may be predicted that studies in which this categorization is made will probably show fewer infections due to gram-positive organisms among low-risk patients, for whom the prolonged use of indwelling catheters may be avoided, the duration of hospitalization is shorter, and the duration and severity of neutropenia is less.
THE IMPACT OF PROPHYLAXIS USE ON THE ETIOLOGY OF BACTEREMIA
Recent clinical trials with minimal prophylaxis. With respect to high-risk febrile neutropenic patients, several recent trials with different percentages of patients receiving prophylaxis demonstrate the impact of varying the proportion of patients who received prophylaxis on the published etiology of bacterial infections in this population. Winston et al. [10] reported the findings of a multicenter, randomized, doubleblinded clinical trial conducted in North America that compared clinafloxacin versus imipenem for the treatment of 541 febrile neutropenic patients who did not receive antibiotic prophylaxis. In contrast to the most-often-quoted preponderance of infection with gram-positive bacteria, in this study, gramnegative organisms, chiefly enteric bacteria, accounted for the majority of isolates (55.6%), with P. aeruginosa constituting a low proportion of these. Infections due to gram-positive organisms were slightly less frequent, with coagulase-negative staphylococci and streptococci causing approximately similar proportions of infections (table 1) . Similar data were reported by Feld et al. [11] , who conducted a randomized, double-blind, clinical trial in North America that compared meropemen with ceftazidime for the treatment of 411 patients with cancer, with prophylaxis administered to ∼40% of patients. Gram-negative organisms constituted 55.9% of isolates, with E. coli being the predominant gram-negative organism. Among gram-positive microorganisms (44.1%), streptococci accounted for the majority of isolates, followed by coagulase-negative staphylococci, with a few cases of bacteremia due to S. aureus (table 1) . Thus, in 2 large trials enrolling in total almost 1000 patients, with prophylaxis administered to !25% of all patients, gram-negative bacteria remained the majority of isolates.
Recent clinical trials with extensive prophylaxis use. In a recent trial conducted in Italy by Del Favero et al. [12] , in which chemoprophylaxis was administered to 90% of adult patients with cancer, gram-positive organisms constituted 66.1% of isolates, confirming their now-often-reported predominance (table 1) . It is striking that 43.8% of all the isolates were coagulase-negative staphylococci. Among gram-negative organisms, which constituted 33.9% of isolates, E. coli predominated, but there was a relatively high percentage of P. aeruginosa isolates. Cordonnier et al. [13] prospectively assessed the epidemiology and risk factors for gram-positive bacterial infections in 513 febrile neutropenic patients in a very recent trial in France. The overall distribution pattern of infections showed a higher prevalence of gram-positive bacterial infections (67.1%), predominantly streptococcal and staphylococcal infections, and fewer infections due to gram-negative organisms (32.9%) (table 1). These investigators began using the nonabsorbable antibiotic colistin for gut decontamination, for prophylaxis among febrile neutropenic patients. On multivariate analysis, infections with gram-positive cocci were significantly associated with receipt of high-dose cytarabine therapy and proton-pump inhibitors, as well as gut decontamination with colistin. Staphylococcal infections were significantly associated with colistin use, and streptococcal infections were associated with diarrhea, receipt of nonabsorbable antifungal agents, highdose cytarabine therapy, and gut decontamination with colistin. The relative risks for streptococcal infections were 2.9, 13.2, and 20.7 for patients with 1, 2, or у3 of these risk factors, respectively. Thus, in recent studies in which there is good documentation of prophylaxis, this appears to be the prime factor determining the etiology of bacterial infections in febrile neutropenia.
A study by Collin et al. [14] examined changes in the incidence and susceptibility of isolates from blood of 519 bone marrow transplant recipients during a 7-year period. Infection rates declined dramatically during that time. Of note, a striking reduction in the proportion of patients with documented grampositive bacterial infections occurred during the study period, from ∼50% of patients in 1991 to ∼10% of patients in 1997. Streptococcus and Staphylococcus species were the most frequent gram-positive organisms isolated. E. coli and Klebsiella species prevailed among gram-negative isolates, followed by b-lactamase-producing bacteria (Enterobacter, Citrobacter, and Serratia species) and P. aeruginosa. This decrease in infections due to gram-positive bacteria could be ascribed to the fact that blactam agents (e.g., penicillin, cefazolin, and erythromycin) and macrolides were used for prophylaxis, in addition to ciprofloxacin. This resulted in a dramatic reduction in the absolute number of patients with infections due to gram-positive organisms. The number of infections due to gram-negative organisms also decreased, although to a lesser degree. Thus, what is isolated is heavily determined by the nature of the prophylaxis used.
Bacterial isolates from low-risk febrile neutropenia. Lowrisk febrile neutropenic patients are not usually given antibiotic prophylaxis; therefore, data from these patients should be free of an antibiotic effect. However, other confounding effects, such as a lower incidence of mucositis, may influence the profile of the isolates recovered-that is, fewer streptococcal species and fecal organisms. A few large studies have investigated the etiology of bacterial infections in this population. The numbers of isolates from these studies have been small, and they have not yielded consistent findings. Gram-negative and grampositive microorganisms were equally prevalent in a comparative study by Freifeld et al. [15] performed in the United States, whereas gram-negative organisms were more frequent in a double-blind, comparative trial by Kern et al. [16] performed under the auspices of the European Organization for Research and Treatment of Cancer, as well as in a study by Madsen et al. [17] . Hence, it seems difficult to predict how the etiology of bacteremia among low-risk febrile neutropenic patients will evolve. The intensity of chemotherapy and the use of longterm indwelling catheters may therefore be the most important determinants.
Antibiotic resistance in microorganisms isolated from febrile neutropenic patients. Much attention is currently paid to resistance issues in the general population, which undoubtedly are, or will be, relevant to febrile neutropenic patients. With respect to gram-positive organisms, resistance to vancomycin among enterococci has emerged as a general problem and is now found among isolates from febrile neutropenic patients, among whom outbreaks of vancomycin-resistant enterococcal infections have been reported in oncology units [18] . In addition, there is concern about the possibility of this resistance being transferred on a larger scale to staphylococci in vitro [19] , as has occurred in vivo [20, 21] . Resistance among viridans streptococci, especially Streptococcus mitis and Streptococcus salivarius, has also become an issue. In a study by Carratalá et al. [22] in Barcelona, only slightly 120% of viridans streptococcal isolates from febrile neutropenic patients remained susceptible to ceftazidime, and ∼40% were susceptible to penicillin. More than 95% were susceptible to vancomycin, whereas susceptibility rates to cefotaxime, erythromycin, and imipenem were ∼50%, 57%, and 67%, respectively.
With respect to gram-negative organisms, P. aeruginosa, rather than "disappearing," as has been occasionally surmised, seems to have a cyclical prevalence. It currently accounts for 18% of gram-negative isolates from patients with cancer at the M. D. Anderson Cancer Center (Houston, TX) [23] . A recent review of infections due to this organism in febrile neutropenic patients over nearly 2 decades points out that the number has not declined, although P. aeruginosa represents 5%-12% of the isolates in the studies reviewed [24] . Of increasing concern is resistance among these isolates, given the historically high mortality associated with inadequately treated P. aeruginosa bacteremia in febrile neutropenic patients [25] . Surveillance studies done by the SENTRY program [26] show that of a total of 6631 P. aeruginosa isolates recovered worldwide during 1997-1999, there were 218 that were multidrug-resistant; susceptibility to some agents used to treat febrile neutropenia, such as cefepime and imipenem, ranged from ∼85% in United States and the Asia-Pacific region to 74% and 72%, respectively, in Europe and 66% and 74%, respectively, in Latin America. Susceptibilities to amikacin and tobramycin were high in the United States and the Asia-Pacific region, 190%, and lower in other regions: 79% and 68%, respectively, in Europe and 69% and 64%, respectively, in Latin America. These data, if applicable to febrile neutropenia, suggest that empirical therapy for P. aeruginosa in some parts of the world will be increasingly unreliable.
Extended-spectrum b-lactamase (ESBL)-producing bacteria have also become a serious problem in some regions of the world [27] [28] [29] . They are resistant mainly to third-generation cephalosporins and, to a lesser degree, to piperacillin-tazobactam. Rates of susceptibility to fourth-generation cephalosporins are usually 80%-90%. It seems intuitive that the isolation of such organisms should lead to an increase in the case-fatality rate; however, ESBL-producing bacteria have not been consistently associated with an increase in mortality [30] . Significant numbers of isolates retrieved from febrile neutropenic patients have been reported only in Malaysia [31] , Taiwan [32] , and Korea [33] . In North America, these organisms have not emerged as a significant problem among patients with cancer. In the initial results of the Cancer Resistance Surveillance Program [34] , a total of 2042 isolates from bloodstream, respiratory, urinary, and skin infections were collected in 33 North American oncological institutions during 2000-2001. The incidence of ESBL-producing phenotypes ranged from 1.6% to 4.6% among E. coli and Klebsiella species. Thus, this problem appears to have been contained in North America.
EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS: IN VITRO ACTIVITIES OF THE MOST COMMONLY USED AGENTS
The role played by the rapid institution of empirical, broadspectrum antibacterial therapy for fever and neutropenia in reducing mortality is now unquestioned, following the report by Schimpff et al. [35] . What is sometimes controversial is the composition of the empirical therapy, especially in light of the resistance issues highlighted above. Monotherapy now holds equal sway with combinations that include an aminoglycoside, at least in the United States [36] . Efforts were made in those guidelines to stress the sparing of vancomycin therapy in light of the resistance issues that have emerged with enterococci. On the other hand, the need for reliable coverage against gram-positive organisms-specifically, streptococci and S. aureus-requires use of agents with the best activity against grampositive organisms. The best reliable coverage against gramnegative organisms continues to be a necessity because of the historically high mortality rates associated with infection with these organisms. Table 2 summarizes rates of susceptibility to the antimicrobials most frequently used in the empirical treatment of infections in febrile neutropenic patients in North America [37, 38] . Although these data, taken from 2 recent publications concerning isolates recovered at cancer centers, give a general picture of the situation in the United States, they may not be applicable to all parts of the world. The highest rates of susceptibility are seen with cefepime and imipenem, which are active against almost 100% of E. coli, Klebsiella pneumoniae, Enterobacter species, and S. aureus isolates and maintain reasonable activity against P. aeruginosa isolates. Imipenem is, however, the most active agent in vitro against gram-negative organisms that produce ESBLs. These agents have already proven useful in clinical practice for treating febrile neutropenic patients [39, 40] . They have a distinct advantage over ceftazidime in their spectrum of coverage against gram-positive organisms. Their use as part of initial empirical regimens should not only protect against most gram-negative organisms but also provide reasonable coverage against gram-positive agents, helping to reduce the need for additional therapy with glycopeptides. If vancomycin is not used as empirical therapy, as suggested by the current guidelines, cefepime and imipenem offer the best activity against b-lactam-susceptible gram-positive agents. Although data from clinical trials and surveillance studies of in vitro activity are a basic guide to the choice of an empirical antibiotic regimen, other factors should be taken into account in each institution, including local environmental characteristics that affect the nosocomial microflora and its resistance patterns, as well as antibiotic toxicity, cost of care, and patient-related factors [41] .
CONCLUSIONS
The etiology of bacteremia among febrile neutropenic patients appears to be in flux in more-recently reported large clinical trials. Studies of patients who received minimal or no prophylaxis show the old picture of predominance of infection with gram-negative organisms, despite all of the other factors that are present and thought to influence a gram-positive bacterial etiology. Studies of populations with high rates of antibiotic prophylaxis show a predominance of bacteremia due to gram-positive organisms. Local factors, such as infection control measures used or climate and humidity, seem to influence the etiology of infections. Less-aggressive chemotherapy, radiation, or other interventions that result in fewer cases of mucositis may change the nature of infections. The greatest impact, however, will come from the continued use of prophylaxis. When prophylaxis is administered, local resistance patterns will affect the etiology of infections. With more carriage of resistant microorganisms in the community, these microorganisms will emerge as primary or secondary causes of infection. Infections with certain bacteria, specifically P. aeruginosa, will continue to be a problem to treat, and other strategies must be developed to deal with them.
